LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Novartis AG

Novartis AG

Fermé

116.68 0.16

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

116.6

Max

116.9

Chiffres clés
By Trading Economics
Revenu	2.7B
Ventes	344M 12B
P/E Moyenne du Secteur	23.59 103.001
BPA	1.31
Marge bénéficiaire	22.178
EBITDA	4.7B

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	+0.21 upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	818M 247B
Ouverture précédente	116.52
Clôture précédente	116.68

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

116.33 / 119.15 Support & Résistance

Novartis AG Graphique

Actualités Associées

26 août 2024, 09:47 UTC

Acquisitions, Fusions, Rachats

Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers

18 juil. 2024, 05:58 UTC

Résultats

Novartis Raises Profit Guidance as Key Drugs Boost Sales -- Update

18 juil. 2024, 05:42 UTC

Résultats

Novartis Raises Profit Guidance as Key Drugs Boost Sales

5 juin 2024, 15:26 UTC

Acquisitions, Fusions, Rachats

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

3 sept. 2024, 14:07 UTC

Market Talk

Novartis Has a Strong Drug Pipeline But Investor Optimism Is Yet to Grow -- Market Talk

19 août 2024, 13:36 UTC

Market Talk

Novartis Well on Track to Achieve Guidance -- Market Talk

14 août 2024, 09:02 UTC

Market Talk

Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk

18 juil. 2024, 11:55 UTC

Résultats

Novartis Reports Near 40% Margin In Q2; Shares Slide -- IBD

18 juil. 2024, 09:40 UTC

Market Talk

Résultats

Novartis 2Q Results Seem Solid, Catalysts in Focus -- Market Talk

18 juil. 2024, 08:45 UTC

Market Talk

Résultats

Novartis Sales Beat Reflects Demand for New Drugs, Older Blockbusters Lag -- Market Talk

18 juil. 2024, 07:48 UTC

Market Talk

Novartis Prostate-Cancer Drug Pluvicto Sales Miss Raises Growth Questions -- Market Talk

18 juil. 2024, 07:01 UTC

Market Talk

Résultats

Novartis Profit Outlook Lift Reflects Blockbuster Drug Sales Boost, Operational Execution -- Market Talk

18 juil. 2024, 05:18 UTC

Résultats

Correct: Novartis 2Q Core Operating Profit $4.95B

18 juil. 2024, 05:03 UTC

Résultats

Novartis Had Seen Net Sales to Grow High-Single to Low Double-digit in 2024

18 juil. 2024, 05:03 UTC

Résultats

Novartis Net Sales Guidance in 2024 Unchanged

18 juil. 2024, 05:03 UTC

Résultats

Novartis Had Seen Core Operating Income to Grow Low Double-Digit to Mid-Teens in 2024

18 juil. 2024, 05:03 UTC

Résultats

Novartis Expects Core Operating Income to Grow Mid- to High Teens in 2024

18 juil. 2024, 05:02 UTC

Résultats

Novartis Raises 2024 Guidance

18 juil. 2024, 05:01 UTC

Résultats

Analysts Had 2Q Core Operating Profit at $4.67B

18 juil. 2024, 05:01 UTC

Résultats

Analysts Had 2Q Sales at $12.22B

18 juil. 2024, 05:01 UTC

Résultats

Novartis 2Q Sales $12.51B

18 juil. 2024, 05:01 UTC

Résultats

Novartis 2Q Core Operating Profit $12.51B

18 juil. 2024, 05:00 UTC

Résultats

Novartis AG 2Q EPS $1.60

18 juil. 2024, 05:00 UTC

Résultats

Novartis AG 2Q Adj EPS $1.97

18 juil. 2024, 05:00 UTC

Résultats

Novartis AG 2Q Net Pft $3.2B

20 juin 2024, 06:35 UTC

Acquisitions, Fusions, Rachats

MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q

20 juin 2024, 06:34 UTC

Acquisitions, Fusions, Rachats

Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May

20 juin 2024, 06:33 UTC

Acquisitions, Fusions, Rachats

Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders

20 juin 2024, 06:32 UTC

Acquisitions, Fusions, Rachats

Novartis Holds Around 91.04% of MorphoSys as of Thursday

20 juin 2024, 06:31 UTC

Acquisitions, Fusions, Rachats

Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders

Comparaison

Variation de prix

Novartis AG prévision

Objectif de Prix

By TipRanks

0.21% hausse

Prévisions sur 12 Mois

Moyen 116.9 USD 0.21%

Haut 125 USD

Bas 97 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

116.33 / 119.15Support & Résistance

Recent bearish events outweigh bullish events.

All events are bullish.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.